Related references
Note: Only part of the references are listed.Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
Wenying Yang et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Acute Blood Glucose Fluctuation Induces Myocardial Apoptosis through Oxidative Stress and Nuclear Factor-κB Activation
Wei Zhang et al.
CARDIOLOGY (2013)
The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats
Zenat K. Salman et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Sex Differences in Insulin Resistance and Cardiovascular Disease Risk
Sun H. Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Scott M. Grundy et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2013)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Review of Insulin-Dependent and Insulin-Independent Agents for Treating Patients With Type 2 Diabetes Mellitus and Potential Role for Sodium-Glucose Co-Transporter 2 Inhibitors
Jeffrey S. Freeman
POSTGRADUATE MEDICINE (2013)
Metformin: an old but still the best treatment for type 2 diabetes
Lilian Beatriz Aguayo Rojas et al.
DIABETOLOGY & METABOLIC SYNDROME (2013)
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Effects of Metformin on the Expression of GLUT4 in Endometrium of Obese Women with Polycystic Ovary Syndrome
Jun Zhai et al.
BIOLOGY OF REPRODUCTION (2012)
Sirtuin 1-Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin
Zhi Zheng et al.
DIABETES (2012)
Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial
Hongbo He et al.
JOURNAL OF HYPERTENSION (2012)
Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)
B. Karamanos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
C. Lamanna et al.
DIABETES OBESITY & METABOLISM (2011)
Weight Beneficial Treatments for Type 2 Diabetes
L. F. Meneghini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile
Marzieh Aghahosseini et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2010)
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
Marc Foretz et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control
Etie S. Moghissi et al.
DIABETES CARE (2009)
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease
Michael Miller et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes
Valmore Bermudez et al.
AMERICAN JOURNAL OF THERAPEUTICS (2008)
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
Markolf Hanefeld
CARDIOVASCULAR DIABETOLOGY (2007)
Insulin dose response analysis of free fatty acid kinetics
Michael D. Jensen et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Acarbose, an α-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation
Kosuke Azuma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data
T Kaiser et al.
DIABETOLOGIA (2004)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
M Hanefeld et al.
EUROPEAN HEART JOURNAL (2004)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters
P Rosenbaum et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension
MH Uehara et al.
DIABETES OBESITY & METABOLISM (2001)
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30
CJ Glueck et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects
E Mannucci et al.
DIABETES CARE (2001)
Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes
A Katsuki et al.
DIABETES CARE (2001)
Metformin treatment corrects vascular insulin resistance in hypertension
S Verma et al.
JOURNAL OF HYPERTENSION (2000)
Share Paper
